NVGN : Summary for Novogen Limited - American Depo - Yahoo Finance

U.S. Markets closed

Novogen Limited (NVGN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.72-0.01 (-0.58%)
At close: 4:00 PM EST
People also watch:
NYMXPRANPBMDBIOCGENE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.73
Open1.75
Bid1.20 x 2500
Ask2.45 x 800
Day's Range1.69 - 1.75
52 Week Range1.49 - 2.85
Volume12,166
Avg. Volume43,590
Market Cap33.46M
Beta0.81
PE Ratio (TTM)-3.28
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

    NASDAQ: NVGN) today announced that it has fully-acquired Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction includes an upfront payment of AU$ 2.1 million, comprising AU$ 600,000 in cash and ordinary fully-paid shares valued at AU$ 1.5 million, with the actual number of shares determined on the basis of the volume-weighted average price of Novogen shares on the ASX in the seven days prior to this announcement. The first two of these milestones provide for the issue of ordinary fully-paid shares valued at AU$ 1.25 million respectively on commencement and successful completion of a phase II clinical trial of GDC-0084, with the actual number of shares determined on the basis of the volume-weighted average price of Novogen shares on the ASX in the seven days prior to satisfaction of the relevant milestone being announced.

  • PR Newswirelast month

    Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma

    NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialise GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway. The lead indication for GDC-0084 is glioblastoma multiforme (GBM), which is the most aggressive form of brain cancer, accounting for approximately 15% of primary brain tumours. Therapies targeting the PI3K pathway have been under development by a number of pharmaceutical and biotechnology companies for several years, in various types of cancer.

  • PR Newswirelast month

    Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

    NASDAQ: NVGN) today announced that it has fully-acquired Glioblast Pty Ltd, a privately-held, neuro-oncology-focused Australian biotechnology company. The transaction includes an upfront payment of AU$ 2.1 million, comprising AU$ 600,000 in cash and ordinary fully-paid shares valued at AU$ 1.5 million, with the actual number of shares determined on the basis of the volume-weighted average price of Novogen shares on the ASX in the seven days prior to this announcement. The first two of these milestones provide for the issue of ordinary fully-paid shares valued at AU$ 1.25 million respectively on commencement and successful completion of a phase II clinical trial of GDC-0084, with the actual number of shares determined on the basis of the volume-weighted average price of Novogen shares on the ASX in the seven days prior to satisfaction of the relevant milestone being announced.